PAVmed is a diversified life sciences holding company that advances medical technologies through independently financed subsidiaries. Its primary asset is Lucid Diagnostics, a commercial-stage diagnostics company focused on early detection of esophageal precancer and cancer. Lucid's core products are the EsoGuard Esophageal DNA Test and the EsoCheck Esophageal Cell Collection Device, which together form a non-invasive screening system for chronic GERD patients at elevated risk for esophageal adenocarcinoma. EsoCheck is a swallowable balloon catheter that collects esophageal cells in a brief in-office procedure; EsoGuard then analyzes those cells via a DNA methylation assay for signs of Barrett's esophagus or cancer. Lucid sells primarily to primary care physicians and gastroenterologists through its own test centers, a satellite program, telemedicine partnerships, and a direct contracting channel targeting self-insured employers. Revenue is driven by EsoGuard test volume at an effective Medicare rate of roughly $1,938 per test. The single biggest business driver is securing broad insurance reimbursement, particularly Medicare coverage, which remains pending. PAVmed's second subsidiary, Veris Health, offers a remote monitoring platform for cancer patients on systemic treatment, operating on a per-patient monthly SaaS model with oncology practices and hospitals. PAVmed operates as a parent holding company under a shared services model, earning management fees from subsidiaries that raise their own capital independently.